$KLRA · Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
More about this company
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-23 | SCHEDULE 13D | BCLS Fund IV Investments, L.P. | 17.4% | Med | filing |
| 2026-04-23 | SCHEDULE 13D | BCPE Perseus Investor, LP | 20.3% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-04-22 | RTW INVESTMENTS, LP (cluster of 5) | 10%-owner | 500,000 | $8,000,000 | Form 4 |
| 2026-04-20 | Koppel Adam (cluster of 5) | director+10%-owner | 1,562,500 | $25,000,000 | Form 4 |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC (cluster of 5) | 10%-owner | 1,562,500 | $25,000,000 | Form 4 |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC (cluster of 5) | 10%-owner | 8,398,438 | $134,375,008 | Form 4 |
| 2026-04-20 | Kaplan Andrew T. (cluster of 5) | director+10%-owner | 8,398,438 | $134,375,008 | Form 4 |